NTLA vs TRIB
Intellia Therapeutics, Inc. and Trinity Biotech PLC, side by side — 9 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | NTLA | TRIB |
|---|---|---|
| Revenue | $67.7M | $61.6M |
| Net income | $-412.7M | $-31.8M |
| Gross margin | · | 34.8% |
| Net margin | −609.9% | −50.7% |
| Return on equity | −53.5% | · |
| Diluted EPS | −$3.81 | · |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | $-395.9M | $-4.6M |
| Equity | $671.4M | · |
| Net debt / equity | · | · |
| Current ratio | 5.08× | 1.28× |
| Revenue CAGR 5y | 3.1% | −7.4% |
| Profit CAGR 5y | · | · |
NTLA and TRIB book revenue within 15% of each other, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
9 years side by side
| Fiscal year | NTLA | TRIB |
|---|---|---|
| FY2024 | $57.9M | $61.6M |
| FY2023 | $36.3M | $56.8M |
| FY2022 | $52.1M | $62.5M |
| FY2021 | $33.1M | $81.1M |
| FY2020 | $58.0M | $102.0M |
| FY2019 | $43.1M | $90.4M |
| FY2018 | $30.4M | $97.0M |
| FY2017 | $26.1M | $99.1M |
| FY2016 | $16.5M | $99.6M |
Bottom line
| Fiscal year | NTLA | TRIB |
|---|---|---|
| FY2024 | $-519.0M | $-31.8M |
| FY2023 | $-481.2M | $-24.0M |
| FY2022 | $-474.2M | $-41.0M |
| FY2021 | $-267.9M | $875,000 |
| FY2020 | $-134.2M | $-6.4M |
| FY2019 | $-474.2M | $-28.9M |
| FY2018 | $-85.3M | $-22.1M |
| FY2017 | $-67.5M | $-40.3M |
| FY2016 | $-31.6M | $-100.6M |
9 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2024 | −$3,678,000 | TRIB |
| FY2023 | −$20,557,000 | TRIB |
| FY2022 | −$10,400,000 | TRIB |
| FY2021 | −$48,096,000 | TRIB |
| FY2020 | −$43,986,000 | TRIB |
| FY2019 | −$47,332,000 | TRIB |
| FY2018 | −$66,601,000 | TRIB |
| FY2017 | −$73,023,000 | TRIB |
| FY2016 | −$83,132,000 | TRIB |
TRIB has reported the higher revenue in every one of these 9 fiscal years. The gap has narrowed since the earliest year compared.
9 of 11 comparable fiscal years — a year missing data on either side is not counted.
9 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2024 | −846.1 pp | TRIB |
| FY2023 | −1261.6 pp | TRIB |
| FY2022 | −840.1 pp | TRIB |
| FY2021 | −808.2 pp | TRIB |
| FY2020 | −225.6 pp | TRIB |
| FY2019 | −198.9 pp | TRIB |
| FY2018 | −257.1 pp | TRIB |
| FY2017 | −219.6 pp | TRIB |
| FY2016 | −153.2 pp | TRIB |
TRIB has kept the higher net margin in every one of these 9 fiscal years.
9 of 11 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
NTLA's net margin has been more volatile than TRIB's over the 9 comparable fiscal years — 395.2 percentage points of standard deviation against 22.2.
9 of 11 comparable fiscal years — a year missing data on either side is not counted.
Year by year
TRIB led in net margin in every one of the 9 comparable fiscal years — a structural lead, not a recent swing.
9 of 11 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
NTLA's return on equity has been more volatile than TRIB's over the 3 comparable fiscal years — 68.4 percentage points of standard deviation against 35.5.
3 of 11 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between NTLA and TRIB over these 3 fiscal years — NTLA led in 2 and TRIB in 1.
3 of 11 comparable fiscal years — a year missing data on either side is not counted.